Tamaulipas Comparative Wound Healing Test Treatment Successfully Concluded

Results Confirm Unique Properties of Hemospray

WITTEN, Germany, October 29 /PRNewswire-FirstCall/ -- The comparative
study of chronic wound treatment at the Hospital Civil of Cd. Victoria,
Tamaulipas, Mexico, was concluded successfully. Due to the significantly
superior therapeutic success the Ministry of Health ordered the control to be
abandoned and moved to Hemospray treatment for ethical reasons. 22 of the 24
patients within the Hemospray group were healed completely, while 22 of the
24 patients of the control group showed no comparable progress. Moreover,
additional patients suffering from diabetic foot disease were successfully
treated with Hemospray. The total healing ratio is significantly higher than
75%.
These results were presented to health system representatives of several
Latin American countries in Mexico City by the Chief Investigator of the
study.
The results are currently being evaluated by the State Health Authorities
of Tamaulipas who sponsored the study.
Apart from this, a considerable share of the patient data were
crosschecked and evaluated by Sangui in Witten. It turned out that these data
confirm the results as previously indicated. Sangui regards this outcome as a
confirmation of the outstanding efforts made by the teams on location and as
a great success of its systematic competence in wound healing.
SanguiBioTech GmbH is a ninety percent subsidiary of Sangui BioTech
International, Inc. (http://www.pinksheets.com: SGBI)
Some of the statements contained in this news release discuss future
expectations, contain projections of results of operation or financial
condition or state other "forward-looking" information. These statements are
subject to known and unknown risks, uncertainties, and other factors that
could cause the actual results to differ materially from those contemplated
by the statements. The forward-looking information is based on various
factors and is derived using numerous assumptions. Important factors that may
cause actual results to differ from projections include, among many others,
the ability of the Company to raise sufficient capital to meet operating
requirements. Words such as "anticipates," "expects," "intends," "plans,"
"believes," "seeks," "estimates," and variations of such words and similar
expressions are intended to identify such forward-looking statements. Unless
required by law, the Company undertakes no obligation to update publicly any
forward-looking statements, whether as a result of new information, future
events or otherwise.
For more information please contact:

Joachim Fleing
Phone: +49(160)741-27-17
Fax: +49(2302)915-191
e-mail: fleing@sangui.de

SOURCE Sangui Bio Tech International Inc.

For more information please contact: Joachim Fleing, Phone: +49(160)741-27-17,
Fax: +49(2302)915-191, e-mail: fleing@sangui.de